Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Hybritech to rid itself of MAb R&D

After years of working to develop monoclonal antibodies for radioimmune therapy and in vivo imaging, the Hybritech Inc. division of Eli Lilly and Co. said it was discontinuing development and looking to license the technology.

Hybritech had submitted one product to the

Read the full 427 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers